Joseph D Symonds1, Amy McTague2. 1. Paediatric Neuroscience Research Group, Royal Hospital for Children, Glasgow, G51 4TF, UK; Medical Veterinary and Life Sciences, University of Glasgow, G12 8QQ, UK. Electronic address: josephsymonds@nhs.net. 2. Institute of Child Health, University Collge London, 30 Guilford St, Holborn, London WC1N 1EH, UK.
Abstract
BACKGROUND: The advent of Next Generation Sequencing (NGS) has led to a redefining of the genetic landscape of the epilepsies. Hundreds of single gene epilepsies have been described. Genes associated with epilepsy involve diverse processes. Now a substantial proportion of individuals with epilepsy can receive a high definition molecular genetic diagnosis. METHODS: In this review we update the current genetic landscape of the epilepsies and categorise the major functional groupings of epilepsy-associated genes. We describe currently available genetic testing approaches. We perform a literature review of NGS studies and review the factors which determine yield in cohorts undergoing testing. We identify factors associated with positive genetic diagnosis and consider the utility of genetic testing in terms of treatment selection as well as more qualitative aspects of care. FINDINGS: Epilepsy-associated genes can be grouped into five broad functional categories: ion transport; cell growth and differentiation; regulation of synaptic processes; transport and metabolism of small molecules within and between cells; and regulation of gene transcription and translation. Early onset of seizures, drug-resistance, and developmental comorbidity are associated with higher diagnostic yield. The most commonly implicated genes in NGS studies to date, in order, are SCN1A, KCNQ2, CDKL5, SCN2A, and STXBP1. In unselected infantile cohorts PRRT2, a gene associated with self-limited epilepsy, is frequently implicated. Genetic diagnosis provides utility in terms of treatment choice closing the diagnostic odyssey, avoiding unnecessary further testing, and informing future reproductive decisions. CONCLUSIONS: Genetic testing has become a first line test in epilepsy. As techniques improve and understanding advances, its utility is set to increase. Genetic diagnosis, particularly in early onset developmental and epileptic encephalopathies, influences treatment choice in a significant proportion of patients. The realistic prospect of gene therapy is a cause for optimism.
BACKGROUND: The advent of Next Generation Sequencing (NGS) has led to a redefining of the genetic landscape of the epilepsies. Hundreds of single gene epilepsies have been described. Genes associated with epilepsy involve diverse processes. Now a substantial proportion of individuals with epilepsy can receive a high definition molecular genetic diagnosis. METHODS: In this review we update the current genetic landscape of the epilepsies and categorise the major functional groupings of epilepsy-associated genes. We describe currently available genetic testing approaches. We perform a literature review of NGS studies and review the factors which determine yield in cohorts undergoing testing. We identify factors associated with positive genetic diagnosis and consider the utility of genetic testing in terms of treatment selection as well as more qualitative aspects of care. FINDINGS:Epilepsy-associated genes can be grouped into five broad functional categories: ion transport; cell growth and differentiation; regulation of synaptic processes; transport and metabolism of small molecules within and between cells; and regulation of gene transcription and translation. Early onset of seizures, drug-resistance, and developmental comorbidity are associated with higher diagnostic yield. The most commonly implicated genes in NGS studies to date, in order, are SCN1A, KCNQ2, CDKL5, SCN2A, and STXBP1. In unselected infantile cohorts PRRT2, a gene associated with self-limited epilepsy, is frequently implicated. Genetic diagnosis provides utility in terms of treatment choice closing the diagnostic odyssey, avoiding unnecessary further testing, and informing future reproductive decisions. CONCLUSIONS: Genetic testing has become a first line test in epilepsy. As techniques improve and understanding advances, its utility is set to increase. Genetic diagnosis, particularly in early onset developmental and epileptic encephalopathies, influences treatment choice in a significant proportion of patients. The realistic prospect of gene therapy is a cause for optimism.
Authors: Marina Trivisano; Alessandro Ferretti; Elizabeth Bebin; Linda Huh; Gaetan Lesca; Aleksandra Siekierska; Ryo Takeguchi; Maryline Carneiro; Luca De Palma; Ilaria Guella; Kazuhiro Haginoya; Ruo Ming Shi; Atsuo Kikuchi; Tomoko Kobayashi; Julien Jung; Lieven Lagae; Mathieu Milh; Marie L Mathieu; Berge A Minassian; Antonio Novelli; Nicola Pietrafusa; Eri Takeshita; Marco Tartaglia; Alessandra Terracciano; Michelle L Thompson; Gregory M Cooper; Federico Vigevano; Laurent Villard; Nathalie Villeneuve; Gunnar M Buyse; Michelle Demos; Ingrid E Scheffer; Nicola Specchio Journal: Epilepsia Date: 2020-07-09 Impact factor: 5.864
Authors: Andrew K Sobering; Dong Li; Jennifer S Beighley; John C Carey; Tyhiesia Donald; Sarah H Elsea; Karla P Figueroa; Jennifer Gerdts; Andre Hamlet; Ghayda M Mirzaa; Beverly Nelson; Stefan M Pulst; Janice L Smith; Flora Tassone; Helga V Toriello; Ruth H Walker; Katherine R Yearwood; Elizabeth J Bhoj Journal: Am J Med Genet C Semin Med Genet Date: 2020-12-04 Impact factor: 3.908
Authors: Scott K Adney; John J Millichap; Jean-Marc DeKeyser; Tatiana Abramova; Christopher H Thompson; Alfred L George Journal: Ann Clin Transl Neurol Date: 2020-08-04 Impact factor: 4.511